Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway
Ruyue Xu, Xinkuang Liu, Amin Li, et al.
Journal of Molecular Medicine (2022) Vol. 100, Iss. 4, pp. 585-598
Closed Access | Times Cited: 21

Showing 21 citing articles:

Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
Xinchen Tian, Tinghao Yan, Fen Liu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 34
IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways
Wenpeng Cai, Yongfang Ma, Song Li, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 16
Multifaceted role of NF-κB in hepatocellular carcinoma therapy: Molecular landscape, therapeutic compounds and nanomaterial approaches
Reena Gupta, Mustafa M. Kadhim, Abduladheem Turki Jalil, et al.
Environmental Research (2023) Vol. 228, pp. 115767-115767
Closed Access | Times Cited: 16
New insights into Notch signaling as a crucial pathway of pancreatic cancer stem cell behavior by chrysin-polylactic acid-based nanocomposite
Eman M. Ragab, Doaa M. El Gamal, Fares F. Elnajjar, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Naringenin: a potential therapeutic agent for modulating angiogenesis and immune response in hepatocellular carcinoma
Wenmei Wu, Xiangyu Qiu, Xiaofan Ye, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101254-101254
Open Access
The current status and future of PD-L1 in liver cancer
Liyuan Hao, Shenghao Li, Jiali Deng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion
Xia Yang, Chunye Huang, Min Zhong, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma
Chenglong Chen, Qianyu Shi, Jiuhui Xu, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 15
CAR-T Cells Targeting Immune Checkpoint Pathway Players
Vita Golubovskaya
Frontiers in Bioscience-Landmark (2022) Vol. 27, Iss. 4
Open Access | Times Cited: 13
MET Oncogene Targeting for Cancer Immunotherapy
A. Lombardi, Dario Sangiolo, Elisa Vigna
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6109-6109
Open Access | Times Cited: 2
Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment
Shuxi Yao, Xinyue Liu, Yanqi Feng, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 9101-9101
Open Access | Times Cited: 2
Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples
Marius Ilié, Véronique Hofman, Christophe Bontoux, et al.
Lung Cancer (2023) Vol. 181, pp. 107230-107230
Open Access | Times Cited: 4
Mechanism of immune escape mediated by receptor tyrosine kinase KIT in thyroid cancer
Zhen Luo, Jin Xu, Dayong Xu, et al.
Immunity Inflammation and Disease (2023) Vol. 11, Iss. 7
Open Access | Times Cited: 4
CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis
Dantong Sun, Lipin Tan, Yongbing Chen, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 1
c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity
Parham Jabbarzadeh Kaboli, Ghazaal Roozitalab, Reyhaneh Farghadani, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
The role and mechanisms of PD-L1 in immune evasion during Talaromyces marneffei infection
Gang Wang, Wudi Wei, Qiang Luo, et al.
International Immunopharmacology (2023) Vol. 126, pp. 111255-111255
Closed Access | Times Cited: 2
AHNAK2 Promotes the Progression of Pancreatic Ductal Adenocarcinoma by Maintaining the Stability of c-MET
Z Chen, Pengbiao Miao, Hongcao Lin, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 431-444
Open Access
Advances in Selective c-MET Kinase Inhibitors: Application of Fused [5,6]-Bicyclic Nitrogen-Containing Cores for Anticancer Drug Design
Mehdi Valipour, Zahra Zakeri Khatir, Adileh Ayati, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117177-117177
Closed Access
MAFLD-related hepatocellular carcinoma: Exploring the potent combination of immunotherapy and molecular targeted therapy
Ziwei Guo, Ziang Yao, Bohao Huang, et al.
International Immunopharmacology (2024) Vol. 140, pp. 112821-112821
Open Access
IL‐6 upregulates the expression of IL‐6R through the JAK2/STAT3 signalling pathway to promote progression of hepatocellular carcinoma
Li Song, Ruyue Xu, Wenpeng Cai, et al.
Scandinavian Journal of Immunology (2023) Vol. 98, Iss. 1
Closed Access | Times Cited: 1
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites
Earle F. Burgess, Chad Livasy, James T. Symanowski, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 41, Iss. 8, pp. 357.e23-357.e29
Closed Access
Page 1

Scroll to top